# The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer

> **NCT05167851** · PHASE2 · UNKNOWN · sponsor: **Yonsei University** · enrollment: 68 (estimated)

## Conditions studied

- Non Small Cell Lung Cancer

## Interventions

- **DRUG:** Lazertinib , a combination group of SBRT
- **DRUG:** Lazertinib single administration group

## Key facts

- **NCT ID:** NCT05167851
- **Lead sponsor:** Yonsei University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-12
- **Primary completion:** 2025-12
- **Final completion:** 2025-12
- **Target enrollment:** 68 (ESTIMATED)
- **Last updated:** 2021-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05167851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05167851, "The Safety and Efficacy of First-line Lazertinib and Locally Ablative Radiotherapy in Patients With Synchronous Oligo-metastatic EGFR-mutant Non-small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT05167851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*